Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells

Published 2019 View Full Article

Authors

Keywords

erlotinib, valproic acid, non-small cell lung cancer, drug resistance, liquisolid formulation

Journal

AAPS PHARMSCITECH

Volume 20, Issue 3, Pages -

Publisher

Springer Nature

Online

2019-03-05

DOI

10.1208/s12249-019-1332-0

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started